

1.3K
Downloads
21
Episodes
For more than 75 years, the American Cancer Society (ACS) has published some of the most respected peer-reviewed journals in oncology.
CancerSpeak, the official podcast of the ACS Journals, brings this legacy to life through conversations with experts in clinical oncology and related disciplines, connecting listeners with the research and perspectives featured across its titles.
Originally launched in 2023 to highlight research from Cancer, the podcast is expanding to feature work across the full ACS journals portfolio, including CA: A Cancer Journal for Clinicians, Cancer Cytopathology, and Pediatric, Adolescent & Young Adult Cancer.
Each episode examines timely topics with leading experts in their fields, including recent studies, new clinical guidance, and major highlights from annual meetings. When possible, episodes incorporate the patient experience, highlighting the real-world impact of the work we publish.
For more than 75 years, the American Cancer Society (ACS) has published some of the most respected peer-reviewed journals in oncology.
CancerSpeak, the official podcast of the ACS Journals, brings this legacy to life through conversations with experts in clinical oncology and related disciplines, connecting listeners with the research and perspectives featured across its titles.
Originally launched in 2023 to highlight research from Cancer, the podcast is expanding to feature work across the full ACS journals portfolio, including CA: A Cancer Journal for Clinicians, Cancer Cytopathology, and Pediatric, Adolescent & Young Adult Cancer.
Each episode examines timely topics with leading experts in their fields, including recent studies, new clinical guidance, and major highlights from annual meetings. When possible, episodes incorporate the patient experience, highlighting the real-world impact of the work we publish.
Episodes
Wednesday Jan 07, 2026
Low-Grade Gliomas: Evolving Approaches to Care
Wednesday Jan 07, 2026
Wednesday Jan 07, 2026
Dr. Priya Kumthekar, Neuro-Oncology Section Editor for CANCER, and Dr. Helen Shih, Radiation Oncology Section Editor for CANCER, discuss the current treatment landscape for low-grade gliomas with a focus on the evolving role of isocitrate dehydrogenase (IDH) inhibitors. Drawing on findings from the INDIGO trial, they reflect on how recent evidence has informed ongoing discussions around the use of IDH inhibitors, alongside their perspectives on treatment planning and real-world clinical considerations. The conversation also emphasizes the importance of engaging patients in shared decision making throughout the course of care.
Drs. Kumthekar and Shih invite investigators in neuro-oncology, radiation oncology, and related disciplines to consider submitting their research to CANCER. Their closing remarks highlight the journal’s global reach, supportive editorial staff, and connection to the mission of the American Cancer Society.
Learn more about submitting your work to CANCER: https://acsjournals.onlinelibrary.wiley.com/journal/10970142/homepage/why-submit
Original music by J.Gilman.
Follow CANCER on social media:
x.com/JournalCancer
instagram.com/acsjournalcancer
linkedin.com/company/acs-journals
No comments yet. Be the first to say something!